<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04337879</url>
  </required_header>
  <id_info>
    <org_study_id>AL2846-I-0004</org_study_id>
    <nct_id>NCT04337879</nct_id>
  </id_info>
  <brief_title>A Study of AL2846 Capsule Combined With Standard Chemotherapy Regimen in Subjects With Advanced Colorectal Cancer</brief_title>
  <official_title>A Phase Ib Study to Evaluate the Efficacy and Safety of AL2846 Capsule Combined With Chemotherapy (mFOLFOX6 or FOLFIRI)Versus Placebo Combined With Chemotherapy in Subjects With Advanced Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to explore the safety, tolerance and efficacy of AL2846 capsules combined
      with mFOLFOLX6 or FOLFIRI standard chemotherapy regimen in subjects with advanced metastatic
      colorectal cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 20, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to 12 month</time_frame>
    <description>PFS defined as the time from the first dose until the first documented progressive disease (PD) or death from any cause, based on investigator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>up to 12 month</time_frame>
    <description>Percentage of participants achieving complete response (CR) and partial response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate（DCR）</measure>
    <time_frame>up to 12 month</time_frame>
    <description>Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>up to 12 month</time_frame>
    <description>The time when the participants first achieved complete or partial remission to disease progression.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Advanced Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>AL2846 + mFOLFOX6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AL2846 capsule administered orally,once daily in 28-day cycle; oxaliplatin 85mg/ ㎡ administered intravenously (IV) on day 1, day 15 in 28-day cycle；calcium folate 400mg/ ㎡ IV on day 1, day 15 in 28-day cycle；5-fu 2800mg/ ㎡ IV on day 1, 2, 15, 16 in 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AL2846 + FOLFIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AL2846 capsule administered orally,once daily in 28-day cycle; irinotecan 180mg/㎡ administered intravenously (IV) on day 1,15 in 28-day cycle; calcium folate 400mg/ ㎡ IV on day 1,15 in 28-day cycle; 5-fu 2800mg/ ㎡ IV on day 1, 2, 15, 16 days in 28-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AL2846</intervention_name>
    <description>AL2846 is a multi-target receptor tyrosine kinase inhibitor, which has obvious selectivity for c-met.</description>
    <arm_group_label>AL2846 + FOLFIRI</arm_group_label>
    <arm_group_label>AL2846 + mFOLFOX6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium folate</intervention_name>
    <description>Calcium folate 400mg/ ㎡ IV on day 1,15 in 28-day cycle</description>
    <arm_group_label>AL2846 + FOLFIRI</arm_group_label>
    <arm_group_label>AL2846 + mFOLFOX6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>5-FU 2800mg/ ㎡ IV on day 1, 2, 15, 16 days in 28-day cycle.</description>
    <arm_group_label>AL2846 + FOLFIRI</arm_group_label>
    <arm_group_label>AL2846 + mFOLFOX6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin 85mg/ ㎡ administered intravenously (IV) on day 1, day 15 in 28-day cycle.</description>
    <arm_group_label>AL2846 + mFOLFOX6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan 180mg/㎡ administered intravenously (IV) on day 1,15 in 28-day cycle.</description>
    <arm_group_label>AL2846 + FOLFIRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -1. Histologically confirmed advanced metastatic colorectal cancer. 2. Has received only
        first-line standard chemotherapy regimen for metastatic disease, and which was failed.

        3. At least one measurable lesion. 4. Has received systemic chemotherapy, palliative
        radiotherapy or other anti-tumor therapy before first dose at least 4 weeks.

        5.18 and 75 years old; Eastern Cooperative Oncology Group (ECOG) performance status of 0 to
        1; Life expectancy ≥ 3 months.

        6. Adequate laboratory indicators. 7. No pregnant or breastfeeding women, and a negative
        pregnancy test. 8. Understood and signed an informed consent form.

        Exclusion Criteria:

          -  1. Diagnosed and/or treated additional malignancy within 5 years with the exception of
             basal cell carcinoma of the skin and carcinoma in situ of the cervix.

             2. Has received radiotherapy, chemotherapy and surgery before and less than 4 weeks
             from the first administration and less than 5 half-lives of oral targeted drugs after
             the completion of treatment.

             3. Has multiple factors that affect oral medications. 4. Has gastroduodenal ulcer,
             ulcerative colitis, intestinal obstruction and other gastrointestinal diseases or
             other conditions judged by the investigator that may cause gastrointestinal bleeding
             or perforation.

             5. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated
             drainage.

             6. Has arterial or deep vein thrombosis events in 6 months. 7. Hypersensitivity to
             AL2846 or its excipient. 8. Imaging (CT or MRI) shows that tumor invades large blood
             vessels or the boundary with blood vessels is unclear.

             9. Has symptomatic brain metastases, spinal cord compression, and cancerous meningitis
             within 8 weeks,or brain or pia mater disease confirmed by CT or MRI examination before
             the first dose.

             10.Has adverse events caused by previous therapy that did not recover to ≤ grade 1,
             with the exception of alopecia or ≥ grade 2 neurotoxicity caused by Oxaliplatin.

             11. Subjects plan to receive FOLFIRI chemotherapy regimen with uridine diphosphate
             glucuronyltransferase homozygous variant or double hybrid variant.

             12. Has drug abuse history that unable to abstain from or mental disorders. 13. Has
             any serious and/or uncontrolled disease. 14. Has received allogeneic organ
             transplants, hematopoietic stem cell transplants or bone marrow transplants.

             15. Has participated in other clinical trials within 4 weeks before the first dose.

             16. According to the investigators' judgment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yunpeng Liu, Doctor</last_name>
    <phone>024-83282256</phone>
    <email>cmu_trial@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Hospital of China Medical University</name>
      <address>
        <city>Shengyang</city>
        <state>Liaoning</state>
        <zip>110011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yunpeng Liu, Doctor</last_name>
      <email>cmu_trial@163.com</email>
    </contact>
    <investigator>
      <last_name>Yunpeng Liu, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 6, 2020</study_first_submitted>
  <study_first_submitted_qc>April 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2020</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

